A response to ‘A rare side‐effect of intravenous salbutamol’, Girgis M and Milner Q, <i>Anaesthesia</i> 2004; 59: 196–7

Соболев, Ю. А.

doi:10.1111/j.1365-2044.2004.03859.x

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forty-two articles [4, reported on 47 patients (Table 1), who were found to have a blood lactic acid level ≥5.0 mmol/L on treatment with a short-acting (N = 46) or a long-acting (N = 1) ß 2 -agonist, which subsequently decreased by ≥3.0 mmol/L or to ≤2.5 mmol/L ( Figure 2). This was noticed 3 to 56, median 13 h later: in 24 cases after discontinuing [4,[9][10][11][14][15][16]18,19,22,24,25,29,[32][33][34]36,38,40,41,47,48], in 17 cases after reducing [12,13,20,22,23,26,28,30,31,35,37,39,42,43,45], and in 6 cases (all of these patients were affected by asthma) without modifying [8,12,17,21,27,46], the dosage of the selective ß 2 -agonist. None of the patients was managed with further drugs potentially associated with hyperlactate...…”

Section: Individual Casesmentioning

confidence: 99%

Selective ß2-Adrenoceptor Agonists and Relevant Hyperlactatemia: Systematic Review and Meta-Analysis

Liedtke

Lava

Milani

et al. 2019

JCM

View full text Add to dashboard Cite

Selective ß2-agonists have been imputed as potential cause of l-hyperlactatemia since the 1970s. To document the prevalence of hyperlactatemia associated with selective ß2-agonists and to investigate the predisposing factors, we searched for published articles until April 2019 pertaining to the interplay of administration of selective ß2-agonists and circulating l-lactic acid in the Excerpta Medica, Web of Science, and the U.S. National Library of Medicine databases. Out of the 1834 initially retrieved records, 56 articles were included: 42 papers reporting individual cases, 2 observational studies, and 12 clinical trials. Forty-seven individual patients receiving a selective ß2-agonist were found to have l-lactatemia ≥5.0 mmol/L, which decreased by ≥3.0 mmol/L or to ≤2.5 mmol/L after discontinuing (N = 24), reducing (N = 17) or without modifying the dosage of the selective ß2-agonist (N = 6). Clinical trials found that l-lactic acid significantly increased in healthy volunteers administered a ß2-agonist. l-lactatemia ≥5.0 mmol/L was observed in 103 (24%) out of 426 patients with asthma or preterm labor managed with a selective ß2-agonist and was more common in patients with asthma (30%) than in premature labor (5.9%). A significant relationship was also noted between l-lactate level and intravenous albuterol dose or its circulating level. In conclusion, relevant l-hyperlactatemia is common on high dose treatment with a selective ß2-agonist.

show abstract

Section: Individual Casesmentioning

confidence: 99%

Selective ß2-Adrenoceptor Agonists and Relevant Hyperlactatemia: Systematic Review and Meta-Analysis

Liedtke

Lava

Milani

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2004

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 19 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

A response to ‘A rare side‐effect of intravenous salbutamol’, Girgis M and Milner Q, Anaesthesia 2004; 59: 196–7

Cited by 2 publications

References 3 publications

Selective ß2-Adrenoceptor Agonists and Relevant Hyperlactatemia: Systematic Review and Meta-Analysis

Selective ß2-Adrenoceptor Agonists and Relevant Hyperlactatemia: Systematic Review and Meta-Analysis

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About